ackground and Aims Limited information is available on long-term outcomes of EUS-guided gastroenterostomy (EUS-GE) and modifications of lumen-apposing metal stents (LAMSs) over time. Methods All consecutive EUS-GEs for malignant indications between 2020 and 2024 were enrolled in a single-center prospective registry (Prospective Registry of Therapeutic, ClinicalTrials.gov NCT04813055). The primary outcomes were EUS-GE dysfunctions and dysfunction-free survival (DyFS) using Kaplan-Meier curves. Endoscopic and radiologic reassessments were used to estimate local modifications and LAMS diameter over time (linear regression). Results A total of 166 EUS-GEs (median age 66 [IQR, 60-73] years; male 53.6%; pancreatic cancer, 74.1%) were included. A 20-mm LAMS dilated to 18 mm was used in 98.8%. Technical and clinical success rates were 98.8% and 95.7%, respectively. Adverse events were registered in 16.3% (procedure-related, 7.2%). Over a median follow-up of 128 (64-245) days, symptom recurrence occurred in 11%, but was related to EUS-GE dysfunctions in 13 of 154 cases (8.4%), after a median of 209 (85-347) days. All endoscopic reinterventions were successful. Estimated DyFS at 6 and 12 months was 96.7% and 82%, respectively. At endoscopic re-evaluations (47 patients, 61 endoscopies), peri-LAMS tissue reactions were observed in 38.3% after 269 (79-390) days whereas LAMS modifications (mostly ingrowth) were observed in 19.1% after 421 (231-560) days. Radiologic follow-up (89 patients, 168 CT scans) revealed a reduction in LAMS diameter of ≈0.21 mm ± 0.03 every month (F test; P < .0001). Conclusions Clinically overt EUS-GE dysfunctions are rare and successfully endoscopically amenable, discouraging scheduled surveillance in malignancies. However, LAMSs show predictable narrowing, sustained by subclinical local reactions, which might inform surveillance in benign indications.
Long-term Outcomes of endoscopic ultrasound-guided Gastroenterostomy (LONG-RANGE study): a prospective cohort study tracking symptom recurrence, reintervention timelines and stent modifications over time / Vanella, G., Frigo, F., Perelli, F., Barà, R., Leone, R., Stasio, R.c., Maisonneuve, P., Partelli, S., Aleotti, F., Orsi, G., Macchini, M., Balzano, G., Reni, M., Falconi, M., Capurs, G., Arcidiacono, P.g.. - In: GASTROINTESTINAL ENDOSCOPY. - ISSN 0016-5107. - (2026), pp. 242-252. [10.1016/j.gie.2026.01.007]
Long-term Outcomes of endoscopic ultrasound-guided Gastroenterostomy (LONG-RANGE study): a prospective cohort study tracking symptom recurrence, reintervention timelines and stent modifications over time
Vanella GPrimo
;Leone R;Partelli S;Aleotti F;Orsi G;Reni M;Falconi M;Capurs GPenultimo
;Arcidiacono PGUltimo
2026-01-01
Abstract
ackground and Aims Limited information is available on long-term outcomes of EUS-guided gastroenterostomy (EUS-GE) and modifications of lumen-apposing metal stents (LAMSs) over time. Methods All consecutive EUS-GEs for malignant indications between 2020 and 2024 were enrolled in a single-center prospective registry (Prospective Registry of Therapeutic, ClinicalTrials.gov NCT04813055). The primary outcomes were EUS-GE dysfunctions and dysfunction-free survival (DyFS) using Kaplan-Meier curves. Endoscopic and radiologic reassessments were used to estimate local modifications and LAMS diameter over time (linear regression). Results A total of 166 EUS-GEs (median age 66 [IQR, 60-73] years; male 53.6%; pancreatic cancer, 74.1%) were included. A 20-mm LAMS dilated to 18 mm was used in 98.8%. Technical and clinical success rates were 98.8% and 95.7%, respectively. Adverse events were registered in 16.3% (procedure-related, 7.2%). Over a median follow-up of 128 (64-245) days, symptom recurrence occurred in 11%, but was related to EUS-GE dysfunctions in 13 of 154 cases (8.4%), after a median of 209 (85-347) days. All endoscopic reinterventions were successful. Estimated DyFS at 6 and 12 months was 96.7% and 82%, respectively. At endoscopic re-evaluations (47 patients, 61 endoscopies), peri-LAMS tissue reactions were observed in 38.3% after 269 (79-390) days whereas LAMS modifications (mostly ingrowth) were observed in 19.1% after 421 (231-560) days. Radiologic follow-up (89 patients, 168 CT scans) revealed a reduction in LAMS diameter of ≈0.21 mm ± 0.03 every month (F test; P < .0001). Conclusions Clinically overt EUS-GE dysfunctions are rare and successfully endoscopically amenable, discouraging scheduled surveillance in malignancies. However, LAMSs show predictable narrowing, sustained by subclinical local reactions, which might inform surveillance in benign indications.| File | Dimensione | Formato | |
|---|---|---|---|
|
PIIS0016510726000349.pdf
solo gestori archivio
Tipologia:
PDF editoriale (versione pubblicata dall'editore)
Licenza:
Tutti i diritti riservati
Dimensione
11.62 MB
Formato
Adobe PDF
|
11.62 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.


